Surrozen (SRZN) Competitors $10.36 -0.65 (-5.90%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SRZN vs. FULC, GLSI, EDIT, THTX, LYEL, TARA, CGEN, SLS, PRQR, and NMRAShould you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include Fulcrum Therapeutics (FULC), Greenwich LifeSciences (GLSI), Editas Medicine (EDIT), Theratechnologies (THTX), Lyell Immunopharma (LYEL), Protara Therapeutics (TARA), Compugen (CGEN), SELLAS Life Sciences Group (SLS), ProQR Therapeutics (PRQR), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. Surrozen vs. Fulcrum Therapeutics Greenwich LifeSciences Editas Medicine Theratechnologies Lyell Immunopharma Protara Therapeutics Compugen SELLAS Life Sciences Group ProQR Therapeutics Neumora Therapeutics Surrozen (NASDAQ:SRZN) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Do analysts recommend SRZN or FULC? Surrozen presently has a consensus price target of $38.50, suggesting a potential upside of 267.37%. Fulcrum Therapeutics has a consensus price target of $8.63, suggesting a potential upside of 96.92%. Given Surrozen's stronger consensus rating and higher possible upside, equities analysts plainly believe Surrozen is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Which has better valuation and earnings, SRZN or FULC? Surrozen has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10.66M3.23-$43.04M-$21.77-0.48Fulcrum Therapeutics$80M2.96-$97.33M-$0.22-19.91 Does the media favor SRZN or FULC? In the previous week, Fulcrum Therapeutics had 2 more articles in the media than Surrozen. MarketBeat recorded 5 mentions for Fulcrum Therapeutics and 3 mentions for Surrozen. Surrozen's average media sentiment score of 1.16 beat Fulcrum Therapeutics' score of 0.92 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in SRZN or FULC? 66.6% of Surrozen shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 45.2% of Surrozen shares are owned by insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer SRZN or FULC? Fulcrum Therapeutics received 92 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 60.87% of users gave Fulcrum Therapeutics an outperform vote while only 28.57% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformSurrozenOutperform Votes628.57% Underperform Votes1571.43% Fulcrum TherapeuticsOutperform Votes9860.87% Underperform Votes6339.13% Which has more risk & volatility, SRZN or FULC? Surrozen has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500. Is SRZN or FULC more profitable? Fulcrum Therapeutics' return on equity of -7.31% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets SurrozenN/A -120.51% -54.68% Fulcrum Therapeutics N/A -7.31%-6.74% SummaryFulcrum Therapeutics beats Surrozen on 9 of the 16 factors compared between the two stocks. Get Surrozen News Delivered to You Automatically Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRZN vs. The Competition Export to ExcelMetricSurrozenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.39M$2.95B$5.47B$7.92BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.4830.0722.5118.54Price / Sales3.23494.82397.62103.35Price / CashN/A168.6838.1834.62Price / Book0.573.176.734.25Net Income-$43.04M-$72.35M$3.22B$248.18M7 Day Performance4.80%0.95%1.58%1.25%1 Month Performance-5.76%8.28%4.05%3.76%1 Year Performance7.05%-22.65%15.75%5.28% Surrozen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRZNSurrozen3.9115 of 5 stars$10.48-4.8%$38.50+267.4%+2.3%$34.39M$10.66M-0.4880Short Interest ↓Positive NewsFULCFulcrum Therapeutics1.7844 of 5 stars$3.57+1.1%$8.63+141.6%-46.0%$135.49M$80M-11.52100Earnings ReportNews CoverageGLSIGreenwich LifeSciences1.8482 of 5 stars$10.04+0.6%$39.00+288.4%-18.7%$133.27MN/A-12.553Short Interest ↑EDITEditas Medicine4.1576 of 5 stars$1.58+2.6%$6.54+313.8%-68.3%$132.26M$32.31M-0.62230Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoverageTHTXTheratechnologiesN/A$2.87+3.6%N/A+118.5%$131.96M$88.67M-28.70140Short Interest ↑LYELLyell Immunopharma3.4151 of 5 stars$0.44-2.0%$1.00+126.8%-78.1%$130.24M$61,000.00-0.56270Upcoming EarningsNews CoveragePositive NewsGap UpTARAProtara Therapeutics2.2489 of 5 stars$3.52-18.5%$20.40+479.5%+17.4%$129.42MN/A-1.2530Analyst ForecastNews CoverageHigh Trading VolumeCGENCompugen2.0582 of 5 stars$1.44-2.7%$4.00+177.8%-17.1%$128.50M$27.86M72.0070Positive NewsSLSSELLAS Life Sciences Group0.8101 of 5 stars$1.41+0.7%N/A+25.0%$128.09M$1M-2.0410Gap UpPRQRProQR Therapeutics2.9094 of 5 stars$1.54+7.7%$9.50+516.9%-14.4%$124.15M$18.91M-4.81180Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsNMRANeumora Therapeutics3.139 of 5 stars$0.76+0.7%$9.29+1,117.6%-91.4%$123.35MN/A-0.41108 Related Companies and Tools Related Companies FULC Competitors GLSI Competitors EDIT Competitors THTX Competitors LYEL Competitors TARA Competitors CGEN Competitors SLS Competitors PRQR Competitors NMRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRZN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRZN Stock Free SRZN Stock Alerts